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Chiral building blocks are valuable intermediates in
the syntheses of natural products and pharmaceuti-
cals. A scalable chemoenzymatic route to chiral dike-
tides has been developed that includes the general
synthesis of a-substituted, b-ketoacyl N-acetylcys-
teamine thioesters followed by a biocatalytic cycle
in which a glucose-fueled NADPH-regeneration sys-
tem drives reductions catalyzed by isolated modular
polyketide synthase (PKS) ketoreductases (KRs). To
identify KRs that operate as active, stereospecific
biocatalysts, 11 isolated KRs were incubated with 5
diketides and their products were analyzed by chiral
chromatography. KRs that naturally reduce small
polyketide intermediates were the most active and
stereospecific toward the panel of diketides. Several
biocatalytic reactions were scaled up to yield more
than 100 mg of product. These syntheses demon-
strate the ability of PKS enzymes to economically
and greenly generate diverse chiral building blocks
on a preparative scale.
INTRODUCTION
Modular polyketide synthases (PKSs) are enzymatic assembly
lines that control the substitution and stereochemistry of
complex polyketides in the biosyntheses of such compounds
as the antibacterial erythromycin, the antifungal amphotericin,
and the immunosuppressant rapamycin (Staunton and Weiss-
man, 2001; Khosla et al., 2007; Smith and Tsai, 2007; Sherman
and Smith, 2006). Many synthetic organic chemists seek to
emulate the reactions they catalyze and obtain the products
they produce; however, if PKS enzymes, themselves, were har-
nessed as biocatalysts, coveted chiral building blocks and bio-
logically active molecules would be more readily accessed.
Libraries of chiral building blocks are highly desired by
synthetic organic chemists to accelerate the synthesis of natural
products and pharmaceuticals (Hilterhaus and Liese, 2007;
Patel, 2008). Such compounds would be particularly helpful inChemistry & Biology 18, 1331–1the syntheses of complex polyketides because the required
synthetic fragments often harbor multiple stereocenters and
are challenging to prepare. The complexity of synthesizing
reduced polyketides can be appreciated by examining the
synthetic routes established for 6-deoxyerythronolide B (6-dEB),
the precursor of erythromycin antibiotics (Masamune et al.,
1981; Myles et al., 1990; Evans et al., 1998; Crimmins and Slade,
2006; Stang and White, 2009). Although several groups over the
last 30 years have worked on the synthesis of this archetypal
macrolide core, the shortest is 22 steps with an overall yield of
7.8% (Stang and White, 2009).
The soil bacterium Saccharopolyspora erythraea synthesizes
6-dEB with DEBS (6-dEB synthase), a PKS that contains diverse
catalytic activities: acyltransferases (ATs) catalyze the trans-
esterification of small organic extender units from acyl-CoAs
onto the PKS, ketosynthases (KSs) catalyze decarboxylative
Claisen condensations that create carbon-carbon bonds
between these extender units and the growing polyketide chain,
ketoreductases (KRs) catalyze stereospecific, NADPH-coupled
reductions of b-keto groups formed through condensation, a
dehydratase (DH) catalyzes an elimination reaction to yield an
olefin, and an enoylreductase (ER) catalyzes the stereospecific,
NADPH-coupled reduction of that olefin (Figure 1A) (Khosla
et al., 2007). Growing polyketides are passed along the PKS
assembly line through trans-thioesterification reactions between
acyl carrier proteins (ACPs) and KSs to a thioesterase (TE) that
catalyzes the cyclization of a heptaketide to yield 6-dEB. Thus,
enzymes in the PKS cooperate to transform seven molecules
of propionate into one molecule of 6-dEB under ambient,
aqueous conditions. As the current syntheses of 6-dEB and
related natural products rely on organic solvents, chiral auxilia-
ries, and metals that can be both expensive and environmentally
harmful, employing PKS enzymes in such syntheses would be
advantageous.
Aldol reactions employed in organic syntheses to form
carbon-carbon bonds and set stereocenters in the same reac-
tion sometimes lack the desired level of stereocontrol. The
equivalent process in PKSs is carefully regulated by two
enzymes: KSs that mediate carbon-carbon bond formation
and KRs that guide the setting of stereocenters. The combina-
tion of stereocenters produced is dependent on the KR type.
KRs that perform reductions yielding L-b-hydroxyl groups are
referred to as ‘‘A-type,’’ and KRs that perform reductions340, October 28, 2011 ª2011 Elsevier Ltd All rights reserved 1331
Figure 1. Employing PKS KRs to Chemoenzymatically Synthesize a Library of Chiral Building Blocks
(A) The DEBS assembly line synthesizes 6-dEB; 9/10 stereocenters are set by KRs that are classified by the combination of stereocenters they produce. LDD,
loading didomain.
(B) GDH helps drive the reduction of diketide-SNACs, regenerating NADPH through the oxidation of D-glucose.
(C) A general synthesis of a-substituted, b-keto diketides was developed. Stereospecific KRs can convert these common intermediates into chiral diketide-
SNACs.
(D) Representatives of the library of diketide chiral building blocks that can be accessed through KR biocatalytic reactions.
See also Figure S1 and Table S1.
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tase-incompetent KRs are referred to as ‘‘C-type’’) (Reid et al.,
2003; Caffrey, 2003; Keatinge-Clay, 2007; Valenzano et al.,
2009). KRs that reduce D-a-substituted intermediates are
denoted with a ‘‘1,’’ whereas KRs that reduce L-a-substituted
intermediates are denoted with a ‘‘2’’ (Keatinge-Clay, 2007).
Thus, an a-substituted, b-keto diketide intermediate can be
reduced to the ‘‘2R,3S’’ product by an A1-type KR, the ‘‘2S,3S’’
product by an A2-type KR, the ‘‘2R,3R’’ product by a B1-type
KR, or the ‘‘2S,3R’’ product by a B2-type KR (Keatinge-Clay
and Stroud, 2006; Keatinge-Clay, 2007; Zheng et al., 2010).
Because KRs can exert control over two stereocenters in one
reduction reaction and, as a family, operate on diverse organic
substrates, they possess extraordinary potential as biocatalysts
(Patel, 2008). At least two studies of KRs as biocatalysts have
been reported; however, the substrates examined were not
very similar to those naturally encountered and the stereochem-
ical purities of the reaction products were not investigated
(Bali et al., 2006; Bali and Weissman, 2006). Analytical-scale
enzymological studies have focused on the substrate analog
(2RS)-methyl-3-oxopentanoyl-S-N-acetylcysteamine (-SNAC),3.1332 Chemistry & Biology 18, 1331–1340, October 28, 2011 ª2011 EReductions of 3mediated by EryKR1, EryKR2, EryKR5, EryKR6,
MycKRA, MycKRB, and TylKR1 revealed that EryKR1 (B2-type)
and TylKR1 (B1-type) were completely stereospecific, whereas
the other KRs produced a mixture of diastereomers (isolated
domains are referred to by their PKSandmodule of origin, except
the mycolactone KRs, which are identified by KR type) (Siskos
et al., 2005; Bali and Weissman, 2006). That from the isolated
KRs examined for their stereospecificity two KRs were identified
that catalyze stereospecific reduction suggested that other
KRs that perform stereocontrolled reductions isolated from
their PKSs could be discovered. If all KR types were available
as biocatalysts, then the full stereochemical diversity naturally
achieved by KRs could be accessed.
Thus, to demonstrate the utility of PKS enzymes in natural
product and pharmaceutical synthesis, we aimed to develop
KRs as biocatalysts and access a library of diketide chiral
building blocks (Figure 1D). Required were both a facile synthetic
route to a-substituted, b-keto diketide thioester analogs of the
polyketide intermediates naturally reduced by KRs as well as
a scalable, economic biocatalytic process that does not require
stoichiometric NADPH for KR-mediated reduction.lsevier Ltd All rights reserved
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teamine thioesters was developed and used to generate diketide
substrates 1–5. An NADPH-regeneration system in which KR-
mediated reductions are driven by glucose was designed.
Eleven isolated KRs were incubated with 1–5 in biocatalytic
reactions and the products were analyzed by chiral chromatog-
raphy. Robust A1-type and A2-type KR biocatalysts were
identified. Several biocatalytic reactions were scaled up, both
with purified KRs as well as KR-containing lysate, to readily
provide 100 mg yields of stereopure chiral building blocks. In
addition to illustrating that building blocks for the synthesis of
natural products and pharmaceuticals can be accessed by
PKS enzymes, the described biocatalytic systems provide PKS
enzymologists access to polyketide substrates and enable





To drive KR-mediated reduction reactions, an NADPH-regener-
ation scheme was employed (Figure 1B). Glucose dehydroge-
nase (GDH) cloned from Bacillus subtilis was used to couple
the oxidation of glucose to the reduction of diketides. GDH
generates NADPH from NADP+ as it oxidizes glucose to gluco-
nolactone (Wong et al., 1985; Kataoka et al., 2003). A high
concentration of glucose establishes a large NADPH:NADP+
ratio that drives the reduction reaction toward completion. At
the pH of the biocatalytic reactions (pH 7.5), most of the gluco-
nolactone produced is hydrolyzed to gluconic acid, which de-
protonates to gluconate. Because decreases in pH result in
GDH and KRs precipitating out of solution, excess buffering
strength is supplied.
General Synthetic Route to a-Substituted, b-Keto
N-Acetylcysteamine Thioesters
The route most commonly employed to generate 3 requires
a costly chiral auxiliary to generate an a-substituted, b-ketoimide
that is subsequently reacted with excess N-acetylcysteamine
(even more expensive than the chiral auxiliary) (Gilbert
et al., 1995). Instead, we access a-substituted, b-keto N-acetyl-
cysteamine thioesters through an efficient and cost-effective
extension of a described route to b-keto N-acetylcysteamine
thioesters (Figure 1C) (Gilbert et al., 1995). After the desired
b-keto N-acetylcysteamine thioester has been obtained from
Meldrum’s acid, an acyl chloride, and N-acetylcysteamine
(generated from cysteamine and acetic anhydride), an a substit-
uent is installed via an alkylation reaction. Thus, the g substituent
of a diketide-SNAC is selected through the acyl chloride, and the
a substituent is selected through the alkyl halide. That the
syntheses yield racemic mixtures of a-substituted, b-ketoacyl-
SNACs is a nonissue because the enantiomers rapidly intercon-
vert in the aqueous environment of the subsequent biocatalytic
reaction.
For isolated KRs to be considered robust biocatalysts, they
should catalyze the reduction of a variety of substrates. Thus,
a panel of five diketide substrates was synthesized to test
the KRs: 3-oxopentanoyl-SNAC (1), (2RS)-methyl-3-oxobuta-
noyl-SNAC (2), (2RS)-methyl-3-oxopentanoyl-SNAC (3), (2RS)-Chemistry & Biology 18, 1331–1methyl-3-oxohexanoyl-SNAC (4), and (2RS)-ethyl-3-oxopenta-
noyl-SNAC (5) (Figure 2). Compared to 3, each of the other
diketides is onemethylene shorter or longer at the a or g position.
Selection of KRs
To identify KRs capable of stereospecifically reducing a range of
diketide substrates, 11 diverse reductase-competent KRs were
selected (see ‘‘Cloning’’ in Experimental Procedures). They
were isolated from modules that do not possess DHs or ERs
because KRs that cooperate with these enzymes are usually
B1-type (Valenzano et al., 2010). MycKRA (A-type), TylKR1
(B1-type), and EryKR1 (B2-type) were chosen, in part, to serve
as positive controls, as how they process 3 has already been
determined (Siskos et al., 2005; Bali and Weissman, 2006). The
selection of the other eight KRs was biased toward A-type KRs
both because isolated A1- or A2-type KRs that stereospecifically
reduce b-ketoacyl-SNAC substrates had previously not been
identified and because A1-type KRs are the most common in
modules without DHs or ERs. All but two of the KRs selected
naturally operate on a-substituted intermediates because we
aimed to set two stereocenters through a single KR-mediated
reduction reaction. KRs were chosen from diverse PKSs
(amphotericin, erythromycin, mycolactone, oleandomycin, pik-
romycin, spinosyn, and tylosin) and from varying locations within
PKS assembly lines (see Figure S1 available online). Thus, the
selection of reductase-competent KRs includes two A-type
KRs that naturally reduce a-unsubstituted intermediates, four
A1-type KRs, two A2-type KRs, one B1-type KR, and two B2-
type KRs. A reductase-incompetent C1-type KR was also
selected as a negative control (Figure S2).
Chiral Chromatography and Establishing Elution Orders
To determine the stereocontrol exerted by KRs when reducing 3,
Leadlay and coworkers synthesized standards that established
the 3a–3d elution order from a chiral column (Holzbaur et al.,
1999). We sought to establish the elution order of 2a–2d
and 4a–4d on the same chiral column to identify the reduced
diketides produced by the 11 KRs in the biocatalytic reactions.
Thus, well-established diastereospecific aldol reactions were
performed to obtain synthetic ‘‘2R,3R,’’ ‘‘2R,3S,’’ and ‘‘2S,3R’’
diketide-SNACs and the elution orders of 2a–2d and 4a–4d
were determined (Evans et al., 1981; Raimundo and Heathcock,
1995) (Figure 3). The products of 2, 3, and 4 elute in the
same order—first the two anti products, then the two syn prod-
ucts: ‘‘2R,3R’’ (B1-type product), ‘‘2S,3S’’ (A2-type product),
‘‘2R,3S’’ (A1-type product), and ‘‘2S,3R’’ (B2-type product)
(Holzbaur et al., 1999).
Syntheses of reduced diketide-SNACs were initiated through
aldol reactions between (4S)-4-benzyl-3-propionyl-2-oxazolidi-
none and the appropriate aldehyde (Figure 3A). In keeping
with the classic Evans syn-selective reaction protocol, one
equivalent of dibutylboron triflate was used to generate the
‘‘2S,3R’’ product (Evans et al., 1981). Heathcock and coworkers
demonstrated that if two equivalents of dibutylboron triflate are
supplied to this reaction, the anti product with the a stereocenter
opposite in configuration to the Evans syn product as well
as some quantity of anti-Evans syn product are generated
(Raimundo and Heathcock, 1995). We utilized this protocol to
generate amixture of ‘‘2R,3R’’ and ‘‘2R,3S’’ products. Chemistry
detailed by Boddy and coworkers was applied to each of the340, October 28, 2011 ª2011 Elsevier Ltd All rights reserved 1333
Figure 2. KR Biocatalytic Assays
Representative chromatograms show the reactions of five of the most active KRs with each of the diketide substrates 1–5 on the left (representative chro-
matograms of the other KRs are illustrated in Figure S2). Chiral building block products are displayed in the middle. The turnover efficiencies of each KR for each
substrate are graphed on the right (‘‘turnover efficiency’’ is defined as the quantity of a product divided by quantities of the products and remaining substrate). The
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Figure 3. Determining Elution Orders
(A) Aldol reactions helped synthesize chiral chromatography standards. After
(i) the propionyl group was added to the chiral auxiliary, then either (ii) the
Heathcock route using two equivalents of dibutylboron triflate or (iii) the
standard Evans route using one equivalent yielded diketide oxazolidinones
that were (iv) hydrolyzed and coupled to NAC.
(B and C) Standards were compared to products from MycKRA (A-type),
TylKR1 (B1-type), and EryKR1 (B2-type) to establish the elution order of
products from KR reactions with 2 and 4. See also Table S3.
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Biocatalysis with Modular PKS Ketoreductasesdiketide-oxazolidinones to hydrolyze the diketides from their
chiral auxiliaries and couple them to NAC (Sharma and Boddy,
2007). The ‘‘2R,3R’’ and ‘‘2R,3S’’ diketide-SNACs were sepa-
rated by reverse-phase HPLC.heights of the bars can be interpreted as relative activities, whereas the ratio of col
a KR on a substrate. Diverse KR types were used in these assays: two A types t
types, one B1 type, two B2 types, and one C1 type (as a negative control). See
Chemistry & Biology 18, 1331–1Analyzing KR Reactions
After reactions in which each of the 11 reductase-competent
KRs was paired with each of 1–5 had been incubated for 1 day
at 22C, they were extracted with ethyl acetate and analyzed
by chiral chromatography (Figure 2; Figure S2). Some reactions
may not have gone to completion due to substrate incompati-
bility, slow kinetics, protein stability, or many other factors.
Because the overall fitness of KRs as biocatalysts was of
interest, a metric of ‘‘turnover efficiency’’ was constructed,
defined as the quantity of a product formed divided by the quan-
tities of all products and unreacted substrate. Relative quantities
were measured by integrating peaks from the 235 nm absor-
bance traces of chiral chromatography runs. Because all reac-
tions were performed in duplicate, the reported turnover efficien-
cies are averages from two runs (in no case was there a deviation
larger than 10%) (Table S2). As 1 could not be accurately quan-
tified (it migrates as an extremely broad peak), the turnover
efficiencies of 1a and 1b were calculated relative to the TylKR1
reaction, which produced the largest product peak. The elution
order for 1a and 1b was assigned as first the ‘‘3R’’ product
then the ‘‘3S’’ product because reactions of active B-type
KRs generated the first peak and reactions of all of the active
A-type KRs (with the exception of AmpKR2) generated the
second peak. The elution order of 5a–5d was assigned in
the same order as the products of 2–4. Added validation for
this assignment comes from the observation that the syn and
anti products of 2–4 have different maximal absorbances (the
anti products maximally absorb at 232 nm, whereas the syn
products maximally absorb at 233 nm): the first two bio-
catalytic products of 5 that elute from the chiral column absorb
as anti products, whereas the last two absorb as syn products.
KR Biocatalysis Results
KRs Usually Maintain Natural Stereocontrol
Active KRs usuallymaintained the stereocontrol anticipated from
their KR types (Figure 2). Most of these KRs even maintained
stereocontrol toward substrate 5, which harbors an uncommon
a-ethyl group. AmpKR2 was identified as a general A1-type KR
biocatalyst, and AmpKR1 was identified as a general A2-type
KR biocatalyst. Because TylKR1 proved to be a general B1-
type KR biocatalyst and EryKR1 proved to be a general B2-
type KR biocatalyst (PikKR1 is even more robust), the desired
spectrum of KR activities was realized. That the KR reactions
are as stereocontrolled as they were determined to be is note-
worthy, because the natural substrates of these enzymes are
polyketide intermediates bound to the pantetheinyl arm pros-
thetic group of holo-ACPs.
KRs that Naturally Reduce Smaller Intermediates
Are Most Active toward Diketide-SNACs
In general, KRs that reduce small polyketides within their native
PKSs, such as AmpKR1, AmpKR2, EryKR1, PikKR1, and
TylKR1, were most active on the panel of diketides. KRs that
reduce larger polyketides within their native PKSs, such as
PikKR5, OleKR6, AmpKR10, and AmpKR11, were nearly inactiveors within a bar can be interpreted as ameasure of the stereocontrol exerted by
hat naturally operate on a-unsubstituted intermediates, four A1 types, two A2
also Figure S2 and Table S2.
340, October 28, 2011 ª2011 Elsevier Ltd All rights reserved 1335
Figure 4. Accessing Diverse Building Block Libraries through PKS
Biocatalysis
Biocatalytic reactions using DHs, ERs, and Module+TEs could enable the
generation of libraries of other building blocks useful in the syntheses of natural
products, such as a-substituted diketides and triketide lactones containing
up to four contiguous stereocenters (representative molecules are shown).
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short-chain polyketide intermediates within their native PKSs
obtain binding energy for catalysis from interactions with the
polyketide.
MycKRA was one of the most active KRs in these studies.
Three modules of the mycolactone PKS contain 99% identical
MycKRA enzymes as a result of duplication events; thus, within
the synthase MycKRA enzymes reduce a diketide, a triketide,
and a hexaketide (Stinear et al., 2004). That both A1-type and
A2-type products were produced when MycKRA was incubated
with a-substituted diketides 2–5 is understandable in that this
enzyme naturally operates on a-unsubstituted intermediates.
MycKRA did not produce B-type products. Broad in its substrate
selectivity, MycKRA is a robust, stereocontrolled A-type KR
biocatalyst.
Deviations from Expected
A few KRs were sensitive to slight differences within the panel of
diketides. TylKR1, which is in general a robust, active B1-type
KR, produced mainly the A2-type product 2b when incubated
with 2, which is one methylene shorter than its natural substrate.
AmpKR2, an A1-type KR, converted the a-unsubstituted dike-
tide 1mainly to a B-type product. Research is ongoing to deter-
mine whether KRs are more active and/or stereocontrolled
toward pantetheine-bound diketides than NAC-bound diketides.
Scaled-Up Reactions
Because KR biocatalysts representing each KR type were iden-
tified that could generate the desired library of diketide chiral
building blocks, we sought to demonstrate that useful quantities
of chiral building blocks could be obtained. AmpKR2 (A1-type),
AmpKR1 (A2-type), TylKR1 (B1-type), and EryKR1 (B2-type)
were each incubated in scaled-up reactions with 3. Over
100 mg of each of 3a, 3b, 3c, and 3d was obtained from these
scaled-up reactions. Because the reactions with lower turnover
efficiencies required significant KR concentrations and the
nickel column purification step only captures a small percentage
of KR in the lysate from overexpressing cells, reactions were
also attempted using lysate. Reactions using the lysate were
complete within 6 hr and also provided more than 100 mg of
chiral product. Both for reactions using pure KRs and KR-con-
taining lysate, KR reactions were as stereocontrolled as in the
smaller-scale reactions.
Building Block Libraries, PKS Biocatalysis,
and PKS Enzymology
As well as containing valuable combinations of stereocenters,
the described building blocks harbor a synthetic handle in the1336 Chemistry & Biology 18, 1331–1340, October 28, 2011 ª2011 Eform of a thioester. This moiety can be converted to a carbox-
ylic acid or an aldehyde or used to couple the diketide to
other fragments through an ester, amide, or ketone linkage,
making thioester-containing building blocks very versatile in the
syntheses of natural products (Bruice et al., 1963; Tokuyama
et al., 1998). The installation of a second synthetic handle on
the other end of the diketide chain is also desirable. Because
the biocatalytic assays reported here revealed that variations
at the g position of the diketide substrates are tolerated by
many KRs, it may be possible to incorporate synthetic handles
such as a terminal chlorine, alcohol, double bond, or triple
bond.
Additional building block libraries may be accessed using
other PKS enzymes as biocatalysts. Because many DHs form
trans double bonds from (2R,3R)-a-alkyl-b-hydroxy intermedi-
ates, preparative quantities of a-substituted, a/b-unsaturated di-
ketides may be accessed by incubating a-substituted, b-keto-
diketide-SNACs with appropriate KRs and DHs (Keatinge-Clay,
2008). As ERs stereospecifically reduce such double bonds,
a-substituted, b-keto-diketide-SNACs could be converted,
through the driving force of an NADPH-regeneration system, to
chiral a-substituted, b-methylene-diketide-SNACs by employing
a combination of KR, DH, and ER biocatalysts (Kwan et al.,
2008). Diketide-SNACs can also be enzymatically converted
to triketide lactones containing four contiguous stereocenters
(Figure 4). Suchmolecules have been generated byModule+TEs
(PKS modules C-terminally fused to EryTE) in quantities analyz-
able by radio-TLC or GC-MS as readout of enzymological
studies (Chen et al., 2006). Recently, we have developed an
economical route to supply extender units accepted by ATs to
in vitro PKS reactions (Hughes and Keatinge-Clay, 2011). Thus,
the scaled-up incubation of reduced, chiral diketide-SNACs
with diverse Module+TEs in the presence of NADPH may yield
libraries of triketide building blocks.
Currently, most experiments on modular PKS enzymes are
performed either in vivo, by expressing PKSs heterologously
and extracting polyketides from the growth medium, or in vitro,
by combining the appropriate enzymes, cofactors, and sub-
strates and then analyzing the reaction products by radio-TLC,
GC-MS, or LC-MS (reduced polyketides are usually invisible
on UV absorbance traces). An experimental platform in which
PKS enzymes can perform catalysis in a controlled setting to
produce quantities of polyketides analyzable by NMR or crystal-
lography is highly desired (the stereocenters of products would
be much more readily determined, for example). Expense has
been the principal deterrent of larger in vitro reactions because
polyketide extender units such as methylmalonyl-CoA and
cofactors like NADPH are costly. However, such biocatalytic
processes as the MatB-catalyzed production of extender units
and GDH-catalyzed regeneration of NADPH should enable
PKS enzymologists to perform in vitro reactions more affordably
under controlled conditions, generating multimilligram quantities
of polyketide products.
SIGNIFICANCE
The scalable production of reduced diketide-SNACs (-S-N-
acetylcysteamines) has been realized through the described
general chemoenzymatic route. A screen of 11 diverse,lsevier Ltd All rights reserved
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Biocatalysis with Modular PKS Ketoreductasesisolated ketoreductases (KRs) toward diketides 1–5 re-
vealed that KRs isolated frommodules that naturally reduce
shorter polyketide intermediates are most active on dike-
tide-SNACs. AmpKR2 and AmpKR1 were identified as
robust A1- and A2-type KR biocatalysts, and TylKR1 and
EryKR1 were shown to be robust B1- and B2-type KR bio-
catalysts. More than 100 mg of each diketide 3a–3d was
produced to demonstrate that quantities of chiral diketide
building blocks useful for natural product and pharmaceu-
tical syntheses could be generated economically and
greenly. Other polyketide synthase (PKS) enzymes such as
dehydratases, enoylreductases, and PKS modules C-termi-
nally fused to EryTE can now be investigated as biocatalysts
in the generation of an even greater diversity of diketide and
triketide building blocks. The described biocatalysis will
also benefit PKS enzymology because it is no longer cost-
prohibitive to perform in vitro reactions that yield significant
quantities of polyketide products as readout.
EXPERIMENTAL PROCEDURES
Cloning
All KRs, with the exception of EryKR1, and GDH were cloned from genomic
DNA (gDNA) (Table S1). Regions of DNA encoding KRs from amphotericin
(Amp), oleandomycin (Ole), pikromycin (Pik), spinosyn (Spn), and tylosin (Tyl)
were amplified from Streptomyces nodosus, Streptomyces antibioticus,
Streptomyces venezuelae, Saccharopolyspora spinosa, and Streptomyces
fradiae gDNA, respectively. N- and C-terminal boundaries were chosen using
the boundaries determined from the structures of EryKR1 and TylKR1
(Keatinge-Clay and Stroud, 2006; Keatinge-Clay, 2007). The region encoding
the KR from the mycolactone (Myc) PKS was amplified from a bacterial artifi-
cial chromosome containing DNA from pMUM001 (Stinear et al., 2004). The
regions encoding the KRs from the erythromycin (Ery) PKS were amplified
from a synthetic gene (Kodumal et al., 2004). GDH was cloned from B. subtilis
gDNA. NdeI and EcoRI restriction sites were designed to flank the amplicons
encoding AmpKR2, AmpKR10, AmpKR11, AmpKR13, EryKR2, OleKR6,
PikKR1, PikKR5, and SpnKR3; NdeI and XhoI restriction sites were designed
to flank the amplicons encoding AmpKR1, EryKR1, TylKR1, and GDH; NheI
and NotI restriction sites were designed to flank the amplicon encoding
MycKRA. All restriction sites were engineered so that histidine tags encoded
by pET28b (Novagen) would be N-terminally fused to the proteins, facilitating
purification.
Protein Expression and Purification
All plasmids were transformed into Escherichia coli BL21(DE3). The cells were
grown in Luria broth with 25 mg/l kanamycin at 37C until they reached an
OD600 of 0.5. They were then cooled to 15
C, induced with 1 mM IPTG, and
grown for an additional 16 hr. Cells were spun down, resuspended in lysis
buffer (10% [w/v] glycerol, 0.5 MNaCl, 30 mM Tris [pH 7.5]), and lysed by soni-
cation. After centrifugation at 30,000 3 g for 30 min, lysate was poured over
nickel-NTA resin (QIAGEN) equilibrated with lysis buffer. Bound protein was
washed with 15mM imidazole in lysis buffer and eluted with 150mM imidazole
in lysis buffer. Proteins were then polished using a Superdex 200 gel filtration
column that was equilibrated with 10% (w/v) glycerol, 150 mM NaCl, 10 mM
Tris (pH 7.5) and concentrated to 200 mM. Protein purity was evaluated by
Coomassie-stained SDS-PAGE gels (Figure S1).
KR Reductions
Biocatalytic Screen
Reactions were performed on 10 mM 1–5 in 10% (w/v) glycerol, 100 mMNaCl,
150 mM HEPES (pH 7.5), 200 mM D-glucose, 100 mM NADP+, 1 mM GDH,
and 5 mM KR in a total volume of 200 ml. Following incubation at 22C
for 1 day, reactions were extracted with 2 3 500 ml ethyl acetate and evapo-
rated. The extracts were resuspended in ethanol prior to analysis by chiral
chromatography.Chemistry & Biology 18, 1331–1Scaled-Up Reactions
Reactions were performed on 50 mM 3 in 10% (w/v) glycerol, 300 mM HEPES
(pH 7.5), 100mMNaCl, 300mMD-glucose, 100 mMNADP+, 1 mMGDH, 50 mM
purified KR in a total volume of 15 ml. All reactions were incubated at 22C for
1 day. Each was determined to be complete by reverse-phase HPLC. After
EtOAc extraction and silica gel chromatography (EtOAc), yields of 75%
were obtained. Reactions were also performed using lysate (50 ml from 6 l
culture) that was not poured over a nickel column but rather dialyzed overnight
at 4C in 10 kDaMWCO cellophane dialysis tubing against 10% (w/v) glycerol,
250 mM NaCl, 30 mM HEPES (pH 7.5). In these reactions, 50 mM 3 was incu-
bated in 10% (w/v) glycerol, 300 mM HEPES (pH 7.5), 100 mM NaCl, 300 mM
D-glucose, 100 mMNADP+, 1 mMGDH in a total volume of 15 ml, but with 5 ml
of the reaction volume being supplied from dialyzed lysate. All reactions were
incubated at 22C for 6 hr. Each was determined to be complete by reverse-
phase HPLC. After EtOAc extraction and silica gel chromatography (EtOAc),
yields of 85% were obtained. Background thioester hydrolysis occurs with
a half-time of 3 days for both reactions with purified KRs and reactions
with KR-containing lysate.
Chiral Chromatography
Extracts of reactions from the biocatalytic screens were separated using
a ChiralCel OC-H column (2503 4.6 mm) on a Beckman Coulter HPLC system
with a 20 ml loop. Solvent systems and flow rateswere optimized for each set of
reactions with a particular diketide-SNAC (Table S3). Substrates and products
were observed at a wavelength of 235 nm.
Synthetic Protocols
General Synthetic Route to a-Substituted, b-Keto Diketide-SNAC
Substrates
N-Acetylcysteamine. Cysteamine hydrochloride (3.05 g, 53.6 mmol, 1 eq.),
potassium hydroxide (1.50 g, 53.6 mmol, 1 eq.), and sodium bicarbonate
(6.75 g, 160.8 mmol, 3 eq.) were added to 50 ml H2O. Acetic anhydride
(2.28 ml, 48.2 mmol, 0.9 eq.) was then added dropwise over 5 min, and the
solution was allowed to stir at 22C for 15 min. The reaction was quenched
with 1 M HCl, and the product was extracted with ethyl acetate (3 3 50 ml),
dried withMgSO4, filtered, and concentrated in vacuo, yielding a clear, viscous
liquid.
Meldrum’s Acid Derivatives. Pyridine (2 eq.) was added to Meldrum’s acid
(1 eq.) in 40 ml dry dichloromethane (DCM) at 0C. Next, the acyl chloride
(1 eq.) was added dropwise over 15 min, turning the solution a dark orange
color, and the reaction was stirred overnight at 22C. The reaction was washed
with 0.1MHCl (33 50ml) and the organic layer was dried withMgSO4, filtered,
and concentrated in vacuo.
a-Unsubstituted Diketide-SNACs. The Meldrum’s acid derivative (1 eq.) and
N-acetylcysteamine (1 eq.) were refluxed in dry toluene for 5 hr. The resulting
solution was then concentrated in vacuo.
a-Substituted Diketide-SNACs. The a-unsubstituted diketide-SNAC (1 eq.)
was dissolved in 50 ml dry THF at 0C. Potassium tert-butoxide (1.2 eq.)
was added. After the alkyl iodide (5 eq.) was injected, the reaction was allowed
to warm to 22C and stir overnight. After the reaction was quenched with
0.1 M HCl, the product was extracted with ethyl acetate (3 3 50 ml), dried
with MgSO4, filtered, and concentrated in vacuo, resulting in a clear, viscous
liquid.
Syntheses of a-Methyl, b-Hydroxyl Diketide-SNAC Standards
(4S)-4-Benzyl-3-Propionyl-2-Oxazolidinone (6). (4S)-benzyl-2-oxazolidinone
(250 mg, 1.41 mmol, 1 eq.) was dissolved in 5 ml dry THF at 78C under
nitrogen. n-butyllithium (0.64 ml of a 2.5 M stock in hexanes, 1.59 mmol,
1.13 eq.) was added dropwise to the cooled solution by syringe and stirred
for 5 min. Propionyl chloride (0.158 ml, 1.81 mmol, 1.28 eq.) was added drop-
wise by syringe, and the solution was stirred at78C for 30 min. The reaction
was warmed to room temperature and stirred for an additional 30 min before
being quenched with 3 ml saturated NH4Cl (aq.). The product was extracted
with DCM (2 3 20 ml), washed with 10 ml saturated NaHCO3 (aq.) and then
10 ml brine, dried with MgSO4, filtered, and concentrated in vacuo to produce
a clear oil (260 mg, 80%). Rf 0.40 (20% EtOAc in hexanes).
(4S,20S,30R)-3-(30-Hydroxy-20-Methylbutanoyl)-4-Benzyl-2-Oxazolidinone (7).
(4S)-4-benzyl-3-propionyl-2-oxazolidinone (6) (560 mg, 2.40 mmol, 1 eq.) was
added to 10ml dryDCMunder nitrogen and cooled to 0C.Dibutylboron triflate340, October 28, 2011 ª2011 Elsevier Ltd All rights reserved 1337
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via syringe. Diisopropylethylamine (0.56 ml, 3.19 mmol, 1.33 eq.) was then
added dropwise over 2 min, and the solution was cooled to78C. After acet-
aldehyde (0.151ml, 270 mmol, 1.12 eq.) was added, the solution was stirred at
78C for 30min, allowed towarm to 0C, and further stirred for 2 hr. A solution
of 3.3 ml Na2HPO4 (1 M, pH 7.4) and 8.3 ml MeOH was added to the reaction,
followed by the dropwise addition of 8.5 ml 2:1 MeOH:30% H2O2 (aq.). After
1.5 hr, organic solvents were evaporated in vacuo and the remaining material
was resuspended in 10 ml 5% NaHCO3 (aq.). The product was extracted in
DCM (3 3 20 ml), washed with 20 ml 5% NaHCO3 (aq.) and then 20 ml brine,
dried with MgSO4, filtered, and concentrated in vacuo to yield a clear oil
(350 mg, 53% after flash chromatography). Flash chromatography was per-
formed with a 15%–30% EtOAc in hexanes gradient. Rf 0.38 (50% EtOAc in
hexanes).
(4S,20S,30R)-3-(30-Hydroxy-20-Methylhexanoyl)-4-Benzyl-2-Oxazolidinone (8).
The synthesis for 7 was followed with the exception that butyrylaldehyde
(0.213 ml, 2.41 mmol, 1.12 eq.) was substituted for acetaldehyde. Flash chro-
matography was performed in the same manner, yielding 241 mg (33%) of the
desired product. Rf 0.67 (50% EtOAc in hexanes).
(4S,20R,30R)-3-(30-Hydroxy-20-Methylbutanoyl)-4-Benzyl-2-Oxazolidinone (9)
and (4S,20R,30S)-3-(30-Hydroxy-20-Methylbutanoyl)-4-Benzyl-2-Oxazolidinone
(10). Synthesis followed that of 7, with the exception that two equivalents of
Bu2BOTf were used (2.4 ml of a 1 M solution in DCM, 2.4 mmol, 2 eq.).
Rf 0.56 and 0.60 (50% EtOAc in hexanes).
(4S,20R,30R)-3-(30-Hydroxy-20-Methylhexanoyl)-4-Benzyl-2-Oxazolidinone (11)
and (4S,20R,30S)-3-(30-Hydroxy-20-Methylhexanoyl)-4-Benzyl-2-Oxazolidinone
(12). Synthesis followed that of 8, with the exception that two equivalents of
Bu2BOTf was added (4.32 ml of a 1 M solution in DCM, 4.32 mmol, 2 eq.). Rf
0.73 and 0.77 (50% EtOAc in hexanes).
(2S,3R)-3-Hydroxy-2-Methylbutanoyl-N-Acetylcysteamine Thioester (13).
Aldol product 7 (187 mg, 0.68 mmol) was dissolved in 3 ml of a 4:1 mixture of
THF:H2O and cooled to 0
C. Slowly, 3 ml of 30% H2O2 was added,
followed by 1 ml saturated LiOH (0.5 g LiOH in 1 ml H2O). The reaction was
left to stir at 0C for 2 hr, at which point Na2SO3 was added until H2O2 was
quenched (bubbling ceased). The aqueous phase was washed with DCM
(2 3 15 ml), and the DCM layers were back-extracted with H2O (1 3 15 ml).
The combined aqueous layers were cooled to 0C and the pH was lowered
to 1 with 6 M HCl. The aldol acid was extracted into EtOAc (3 3 20 ml), dried
withMgSO4, filtered, and concentrated in vacuo (as the aldol acid is somewhat
volatile, the solution was only concentrated to 1 ml). 1-ethyl-3-(3-dimethylami-
nopropyl)carbodiimide (211.1 mg, 1.36 mmol, 2 eq.) was added to the solution
under nitrogen at 0C. NAC (96.8 mg, 0.81 mmol, 1.2 eq.) and a few crystals
of 4-dimethylaminopyridine were added. After 4 hr at 0C, the reaction
was quenched with 5 ml H2O. Product was extracted into EtOAc (3 3 15 ml),
washed with 5 ml brine, dried with MgSO4, and filtered. A yellowish oil was
produced after concentration in vacuo (50 mg, 47%). Rf 0.20 (EtOAc).
(2S,3R)-3-Hydroxy-2-Methylhexanoyl-N-Acetylcysteamine Thioester (14).
14was synthesized in the samemanner as 13 from 8 (81%). Rf 0.35 (in EtOAc).
(2R,3R)-3-Hydroxy-2-Methylbutanoyl-N-Acetylcysteamine Thioester (15)
and (2R,3S)-3-Hydroxy-2-Methylbutanoyl-N-Acetylcysteamine Thioester (16).
15 and 16 were synthesized in the same manner as 13 from a mixture of 9
and 10 (33%, 15 + 16). They were then separated by reverse-phase HPLC
on a semipreparative C18 column (BondClone, 300 3 7.8 mm; Phenomenex)
connected to a Waters 1525 HPLC system through a gradient of 15%–
100% B over 30 min, where the mobile phases were (A) H2O with 0.1% TFA
and (B) MeOH with 0.1% TFA, pumped at a flow rate of 2 ml/min. Rf 0.15
and 0.20 (in EtOAc).
(2R,3R)-3-Hydroxy-2-Methylhexanoyl-N-Acetylcysteamine Thioester (17)
and (2R,3S)-3-Hydroxy-2-Methylhexanoyl-N-Acetylcysteamine Thioester (18).
17 and 18 were synthesized in the same manner as 13 from a mixture of 11
and 12 (85%, 17 + 18). They were then separated as described for 15 and
16. Rf 0.30 and 0.35 (in EtOAc).
Characterization via NMR and LC-MS
NMRwasperformedeither on aVarianMercury 400MHzor aVarian INOVA500
MHz instrument. LC-MS was performed on an Agilent Technologies 1200
Series HPLC with a Gemini C18 column (5 mm, 2 3 50 mm; Phenomenex)
coupled to an Agilent Technologies 6130 quadrupole mass spectrometer sys-1338 Chemistry & Biology 18, 1331–1340, October 28, 2011 ª2011 Etem equipped with an electrospray-ionization source. A 5%–95% B gradient
over 12 min at a flow rate of 0.7 ml/min was run in which the mobile
phaseswere (A)H2Owith 0.1% formic acid and (B) acetonitrilewith 0.1% formic
acid.
3-Oxopentanoyl-N-Acetylcysteamine Thioester (1). 1H NMR (400 MHz,
CDCl3) d 1.08 (t, 3H, J = 7.4 Hz, CH3), 1.96 (s, 3H, CH3-C=O), 2.55 (q, 2H,
J = 7.4 Hz C-CH2-C=O), 3.00–3.10 (m, 2H, S-CH2), 3.4–3.5 (m, 2H, N-CH2),
3.7 (s, 2H, O=C-CH2-C=O), 5.88 (br s, 1H, NH). ESI-MS expected mass:
218.3; observed mass: 218.2.
3-Oxobutanoyl-N-Acetylcysteamine Thioester. 1H NMR (400 MHz, CDCl3)
d 1.92 (s, 3H, CH3-C(=O)-N), 2.20 (s, 3H, CH3-C=O), 2.93–3.16 (m, 2H,
S-CH2), 3.36–3.42 (m, 2H, N-CH2), 3.62 (s, 2H, O=C-CH2-C=O), 5.99 (br s,
1H, NH).
(2RS)-Methyl-3-Oxobutanoyl-N-Acetylcysteamine Thioester (2). 1H NMR
(400 MHz, CDCl3) d 1.33 (d, 3H, J = 7.5 Hz, CH3-C-(C=O)2), 1.90 (s, 3H,
CH3-C(=O)-N), 2.19 (s, 3H, CH3-C=O), 2.95–3.08 (m, 2H, S-CH2), 3.30–3.46
(m, 2H, N-CH2), 3.71 (q, 1H, J = 7.5 Hz, O=C-CH-C=O), 5.87 (br s, 1H, NH).
ESI-MS expected mass: 218.3; observed mass: 218.4.
(2RS)-Methyl-3-Oxopentanoyl-N-Acetylcysteamine Thioester (3). 1H NMR
(400 MHz, CDCl3) d 1.08 (t, 3H, J = 7.5 Hz, CH3), 1.38 (d, 3H, J = 7.5 Hz,
CH3-C-(C=O)2), 1.96 (s, 3H, CH3-C=O), 2.48–2.68 (m, 2H, C-CH2-C=O),
3.00–3.14 (m, 2H, S-CH2), 3.36–3.52 (m, 2H, N-CH2), 3.79 (q, 1H, J = 7.5 Hz,
O=C-CH-C=O), 5.92 (br s, 1H, NH). ESI-MS expected mass: 232.3; observed
mass: 232.4.
3-Oxohexanoyl-N-Acetylcysteamine Thioester. 1H NMR (400 MHz, CDCl3)
d 0.90–1.00 (m, 3H, CH3), 1.55–1.70 (m, 2H, C-CH2-C), 1.96 (s, 3H, CH3-C=O),
2.48–2.60 (m, 2H, C-CH2-C=O), 3.00–3.14 (m, 2H, S-CH2), 3.40–3.52 (m, 2H,
N-CH2), 3.70 (s, 2H, O=C-CH2-C=O), 5.92 (br s, 1H, NH).
(2RS)-Methyl-3-Oxohexanoyl-N-Acetylcysteamine Thioester (4). 1H NMR
(400 MHz, CDCl3) d 0.85 (t, 3H, J = 7.6 Hz, CH3), 1.33 (d, 3H, J = 7.9 Hz,
CH3-C-(C=O)2), 1.50–1.60 (m, 2H, C-CH2-C), 1.98 (s, 3H, CH3-C=O), 2.45
(m, 2H, C-CH2-C=O), 2.95–3.12 (m, 2H, S-CH2), 3.34–3.52 (m, 2H, N-CH2),
3.74 (q, 1H, J = 7.9 Hz, O=C-CH-C=O), 5.92 (br s, 1H, NH). ESI-MS expected
mass: 246.3; observed mass: 246.4.
(2RS)-Ethyl-3-Oxopentanoyl-N-Acetylcysteamine Thioester (5). 1H NMR
(400 MHz, CDCl3) d 0.94 (t, 3H, J = 7.3 Hz, CH3), 1.17 (t, 3H, J = 8.4 Hz,
CH3-C-C=O), 1.88–1.98 (m, 2H, C-CH2-C-(C=O)2), 2.15 (s, 3H, CH3-C=O),
2.48–2.66 (m, 2H, C-CH2-C=O), 3.01–3.20 (m, 2H, S-CH2), 3.41–3.58 (m, 2H,
N-CH2), 3.68–3.74 (m, 1H, O=C-CH-C=O), 6.27 (br s, 1H, NH). ESI-MS
expected mass: 246.3; observed mass: 246.4.
(4S)-4-Benzyl-3-Propyl-2-Oxazolidinone (6). 1H NMR (400 MHz, CDCl3)
d 1.22 (t, 3H, J = 8.0 Hz, CH3), 2.76–2.82 (m, 1H, one of CH2-Ph), 2.90–3.05
(m, 2H, CH2-C=O), 3.31 (dd, 1H, J = 15.2 Hz, J = 5.5 Hz, one of CH2-Ph),
4.16–4.23 (m, 2H, CH2-O), 4.66–4.70 (m, 1H, CH-N).
(4S,20S,30R)-3-(30-Hydroxy-20-Methylbutanoyl)-4-Benzyl-2-Oxazolidinone (7).
1HNMR (400MHz, CDCl3) d 1.23 (d, 3H, J = 7.4Hz, CH3), 1.28 (d, 3H, J = 6.1Hz,
CH3-C-C=O), 2.76–2.82 (m, 1H, one of CH2-Ph), 2.93 (br s, 1H, OH), 3.26 (dd,
1H, J = 12.3 Hz, J = 3.3 Hz, one of CH2-Ph), 3.75 (dq, 1H, J = 9.8 Hz,
J = 3.1 Hz, CH), 4.16–4.23 (m, 2H, CH2-O), 4.65–4.69 (m, 1H, CH-N).
(4S,20S,30R)-3-(30-Hydroxy-20-Methylhexanoyl)-4-Benzyl-2-Oxazolidinone (8).
1H NMR (400 MHz, CDCl3) d 0.94 (t, 3H, J = 7.2 Hz, CH3), 1.30 (d, 3H, CH3-C-
C=O), 1.35–1.45 (m, 1H, one of C-CH2-C), 1.45–1.58 (m, 1H one of C-CH2-
C), 2.75–2.81 (m, 1H, one of CH2-Ph), 2.84 (d, 1H, OH), 3.26 (dd, 1H,
J = 13.7 Hz, J = 3.1 Hz, one of CH2-Ph), 3.76 (dq, 1H, J = 7.2 Hz, J = 2.6 Hz,
CH), 3.95–4.00 (m, 1H, CH-C=O), 4.17–4.27 (m, 2H, CH2-O), 4.68–4.74
(m, 1H, CH-N).
(4S,20R,30R)-3-(30-Hydroxy-20-Methylbutanoyl)-4-Benzyl-2-Oxazolidinone (9).
1HNMR (400MHz, CDCl3) d 1.22 (d, 3H, J = 5.6Hz, CH3), 1.32 (d, 3H, J = 6.2Hz,
CH3-C-C=O), 2.56 (d, 1H, J = 7.4 Hz one of CH2-Ph), 2.82 (br s, 1H, OH),
3.28–3.35 (m, 1H, one of CH2-Ph), 3.90–3.95 (m, 1H, CH), 3.96–4.00 (m, 1H,
CH-C=O), 4.15–4.25 (m, 2H, CH2-O), 4.67–4.72 (m, 1H, CH-N).
(4S,20R,30R)-3-(30-Hydroxy-20-Methylhexanoyl)-4-Benzyl-2-Oxazolidinone (11).
1H NMR (400 MHz, CDCl3) d 0.94 (t, 3H, CH3), 1.20 (d, 3H, J = 7.2 Hz, CH3-C-
C=O), 1.35–1.45 (m, 1H, one of C-CH2-C), 1.45–1.58 (m, 1H one of C-CH2-
C), 2.75–2.82 (m, 1H, one of CH2-Ph), 2.91 (d, 1H, J = 7.2 Hz, OH), 3.31 (dd,
1H, J = 7.9 Hz, J = 3.1 Hz, one of CH2-Ph), 3.85 (dq, 1H, J = 7.2 Hz, J =
2.7 Hz, CH), 3.95–4.04 (m, 1H, CH-C=O), 4.15–4.26 (m, 2H, CH2-O), 4.66–
4.74 (m, 1H, CH-N).lsevier Ltd All rights reserved
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1H NMR (500 MHz, CDCl3) d 1.22 (d, 3H, J = 7.6 Hz, CH3), 1.24 (d, 3H, CH3-
C-C=O), 2.01 (s, 3H, CH3-C=O), 2.70–2.75 (m, 1H, CH-C=O), 3.00–3.10
(m, 2H, S-CH2), 3.42–3.53 (m, 2H, N-CH2), 3.70–3.79 (m, 1H, CH), 5.93 (br s,
1H, NH). ESI-MS expected mass: 220.3; observed mass: 220.2.
(2S,3R)-3-Hydroxy-2-Methylhexanoyl-N-Acetylcysteamine Thioester (14).
1H NMR (500 MHz, CDCl3) d 0.94 (t, 3H, J = 7.7 Hz, CH3), 1.22 (d, 3H, J =
7.7 Hz, CH3-C-C=O), 1.50–1.60 (m, 1H, one of C-CH2-C), 1.60–1.70 (m, 1H
one of C-CH2-C), 1.95 (s, 3H, CH3-C=O), 2.70–2.75 (m, 1H, CH-C=O), 3.00–
3.08 (m, 2H, S-CH2), 3.40–3.52 (m, 2H, N-CH2), 3.92–3.98 (m, 1H, J =
5.4 Hz, CH), 5.86 (br s, 1H, NH). ESI-MS expected mass: 248.3; observed
mass: 248.4.
(2R,3R)-3-Hydroxy-2-Methylbutanoyl-N-Acetylcysteamine Thioester (15).
1H NMR (500 MHz, CDCl3) d 1.22 (d, 3H, J = 7.7 Hz, CH3), 1.24 (d, 3H, CH3-
C-C=O), 1.96 (s, 3H, CH3-C=O), 2.70–2.76 (m, 1H, CH-C=O), 3.01–3.14
(m, 2H, S-CH2), 3.47–3.58 (m, 2H, N-CH2), 3.79–3.83 (m, 1H, CH), 6.26 (br s,
1H, NH). ESI-MS expected mass: 220.3; observed mass: 220.2.
(2R,3R)-3-Hydroxy-2-Methylhexanoyl-N-Acetylcysteamine Thioester (17).
1H NMR (500 MHz, CDCl3) d 0.94 (t, 3H, J = 7.2 Hz, CH3), 1.22 (d, 3H, J =
6.9 Hz, CH3-C-C=O), 1.38–1.46 (m, 1H, one of C-CH2-C), 1.46–1.56 (m, 1H
one of C-CH2-C), 2.01 (s, 3H, CH3-C=O), 2.72–2.79 (m, 1H, CH-C=O),
3.01–3.10 (m, 2H, S-CH2), 3.43–3.55 (m, 2H, N-CH2), 3.72–3.78 (m, 1H, CH),
6.07 (br s, 1H, NH). ESI-MS expected mass: 248.3; observed mass: 248.4.
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